Citadel Advisors LLC Has $6.87 Million Stake in Luminex Co. (LMNX)
Citadel Advisors LLC lifted its position in Luminex Co. (NASDAQ:LMNX) by 43.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 337,847 shares of the medical instruments supplier’s stock after purchasing an additional 102,587 shares during the quarter. Citadel Advisors LLC owned 0.77% of Luminex worth $6,868,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pinebridge Investments L.P. grew its holdings in shares of Luminex by 8.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 5,266 shares of the medical instruments supplier’s stock worth $111,000 after purchasing an additional 405 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in shares of Luminex by 92.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 7,895 shares of the medical instruments supplier’s stock worth $166,000 after purchasing an additional 3,785 shares during the last quarter. Sei Investments Co. grew its holdings in shares of Luminex by 38.7% in the 2nd quarter. Sei Investments Co. now owns 8,245 shares of the medical instruments supplier’s stock worth $174,000 after purchasing an additional 2,299 shares during the last quarter. First Quadrant L P CA bought a new stake in shares of Luminex in the 3rd quarter worth about $173,000. Finally, SG Americas Securities LLC grew its holdings in shares of Luminex by 37.4% in the 2nd quarter. SG Americas Securities LLC now owns 9,726 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 2,649 shares during the last quarter. 79.32% of the stock is currently owned by institutional investors and hedge funds.
Luminex Co. (NASDAQ LMNX) opened at $21.58 on Thursday. The stock has a market cap of $962.59, a PE ratio of 37.67, a P/E/G ratio of 2.74 and a beta of 0.18. Luminex Co. has a 52-week low of $17.68 and a 52-week high of $22.42.
Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.06. The business had revenue of $74.14 million for the quarter, compared to the consensus estimate of $74.38 million. Luminex had a net margin of 9.52% and a return on equity of 6.01%. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.21 EPS. equities research analysts expect that Luminex Co. will post 0.49 earnings per share for the current year.
In related news, Director G Walter Loewenbaum II sold 50,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $21.79, for a total transaction of $1,089,500.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.90% of the stock is owned by corporate insiders.
Several equities research analysts have recently weighed in on the stock. TheStreet lowered shares of Luminex from a “b” rating to a “c+” rating in a report on Monday, August 7th. BidaskClub lowered shares of Luminex from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. ValuEngine raised shares of Luminex from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Jefferies Group reaffirmed a “hold” rating and issued a $21.00 target price on shares of Luminex in a report on Friday, October 20th. Finally, Zacks Investment Research raised shares of Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 target price on the stock in a report on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a strong buy rating to the stock. Luminex currently has a consensus rating of “Hold” and a consensus target price of $20.00.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).
Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.